These leukemias exhibit a distinct expression profile compared with other acute leukemia subtypes, and most rearrangements juxtapose BCL11B to super-enhancers, resulting in BCL11B overexpression that serves as a biomarker at diagnosis [23,34]. This evidence concerns the gene BCL11B and leukemia.